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Cyclic AMP regulates a multitude of cellular responses and orchestrates a network of 
intracellular events. In the heart, cAMP is the main second messenger of the β- adrenergic 
receptor (β-AR) pathway producing positive chronotropic, inotropic and lusitropic effects 
during sympathetic stimulation. cAMP is controlled by two families of enzymes with 
opposite actions: adenylyl cyclases which control cAMP production and phosphodiesterases 
(PDEs) which control its degradation. The large number of families and isoforms of these 
enzymes, their different localization within the cell and their organization in macromolecular 
complexes around A kinase-anchoring proteins and PKA substrates leads to a high level 
of compartmentation, both in space and 
time, of cAMP signaling in cardiac myocytes.
1
 
 
Eleven PDE families including 21 genes and about 100 isoforms have been identified so far, 
and they are classified based on their primary amino acid sequence as well as kinetic and 
regulatory properties.
2 
PDEs share a conserved catalytic domain (C- domain) marked by 
approximately 25–52% AA sequence identity, but differ markedly in their regulatory domain 
(N-domain). Some PDE families selectively hydrolyze cAMP (PDE4, 7 and 8) or cGMP 
(PDE5, 6, and 9), while others are promiscuous (PDE1, 2, 3, 10, 11). Out of these 11 PDE 
families, 6 are expressed in cardiac myocytes: PDE1, PDE2, PDE3, PDE4, PDE5 and PDE8. 
In two papers published in this issue of Circulation,
3, 4 
two independent groups confirm 
PDE1 as an important regulator of cardiomyocyte physiology and establish this enzyme 
family as a potential therapeutic target for newly synthesized inhibitors to achieve 
cardioprotection and improve cardiac function in heart failure (HF). 
PDE1 is present in the first peak of elution observed upon separation of PDEs from various 
tissues using high-performance anion-exchange chromatography, which explains its name. 
The PDE1 family is encoded by three genes: pde1a, b and c. They have alternative promoters 
and give rise to a multitude of proteins by alternative splicing. In humans, PDE1A and 1B 
preferentially degrade cGMP, whereas PDE1C hydrolyzes cAMP and cGMP with high 
affinity. PDE1 is activated by the Ca
2+
/CaM complex which binds to the two regulatory 
domains in the N-terminal region. Phosphorylation of the enzyme by PKA or CaMKII near 
the regulatory domains decreases the affinity of PDE1 for Ca
2+
/CaM, and thus confers  
negative feedback for its activity. 
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Cardiac PDE1 was initially thought to be expressed in nonmyocyte cells until the presence of 
PDE1C isoform was convincingly established in the cytosol of human cardiomyocytes.
5 
Later, the presence of both PDE1A and C was shown in cardiomyocytes.
6 
However, despite 
a high level of expression, the functional role of PDE1 in cardiomyocytes has remained poorly 
understood, likely because of the lack of selective inhibitors. Yet, pde1c gene deletion was 
shown to reduce apoptosis in vitro in a cAMP/PKA- and PI3K/AKT-dependent manner and 
to attenuate cardiac remodeling and dysfunction induced by transverse aortic constriction in 
mice.
7 
Accordingly, vinpocetine, a pan-PDE1 inhibitor, prevents myocyte hypertrophy, 
fibroblast activation by TGF-β and fibrotic gene expression and hence blunts pathological 
remodeling induced by chronic stimulation with angiotensin II.
8 
From these results, PDE1 was proposed as a therapeutic target in HF, especially because 
PDE1C was found to be increased in a rodent model of HF and in human diseased heart 
tissue.
7 
However, mechanisms underlying the cardioprotection conferred by PDE1 inhibition 
remained to be determined. This is the point addressed by Zhang et al.,
4 
who elucidated the 
molecular elements of the cAMP signaling pathway modulated by PDE1C which promote 
cardiomyocyte survival. Cardiomyocyte death is associated with cardiac diseases from 
different etiologies. The authors demonstrate that PDE1C deficiency promotes survival of 
cardiomyocytes subjected to various treatments known to evoke cell death, such as chronic 
exposure to isoproterenol, angiotensin II, H2O2 or doxorubicin. With a nice set of 
experiments, they linked the cardioprotective effects of PDE1C downregulation to the 
adenosine A2 receptors (A2R), both the A2AR and A2BR which are coupled to the 
Gαs/cAMP signaling pathway. Additionally, they provide evidence implicating TRPC 
channels, in particular TRPC3, which allows Ca
2+ 
influx into the cardiomyocyte to activate 
Ca
2+
/CaM-stimulated PDE1C which leads to cardiomyocyte death/apoptosis by degrading 
cAMP. They also show that PDE1C is part of a multiprotein complex including TRPC3 and 
A2R, which suggests that it controls specifically the cAMP emanating from these receptors. 
Thus, its inhibition (combined with A2R activation and/or TRPC3 inhibition) promotes cell 
survival (Figure).  
However, because PDE1 represents a major PDE activity in human heart,
1 
inotropic effects 
of its inhibition, accompanied by perturbation of Ca
2+ 
homeostasis, would be anticipated. 
While this point is not addressed by Zhang et al., this is the main focus of the second 
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publication appearing in this issue of Circulation. Hashimoto et al. unveil improved cardiac 
output upon acute administration of a newly developed specific inhibitor of PDE1C named 
ITI-214.
3 
In healthy and HF dogs and rabbits, which represent valuable preclinical models, 
they report for the first time positive chronotropic, inotropic and lusitropic effects, as well as 
vasorelaxant effects, of the PDE1 inhibitor. The effect is attributed to PDE1C as dogs and 
rabbits express predominantly PDE1C in the heart, similar to humans, and also because most 
of these effects were not seen in mice which express predominantly the PDE1A isoform. 
Interestingly, these positive outcomes in vivo were prevented by A2BR antagonism, 
confirming the implication of the A2R signaling as proposed by Chen Yan’s group.
4 
Surprisingly, Hashimoto et al. failed to observe noticeable inotropic effects of A2R 
activation at the cellular level, so it remains unclear whether the inotropic and lusitropic 
effects produced by ITI-214 in rabbit cardiomyocytes are related to an increase in the cAMP 
emanating specifically from these receptors. Also, while the authors confirmed that PDE3 is 
crucial to control the β-AR stimulation of intracellular Ca2+ and contraction, PDE1 
inhibition exerted an inotropic effect only upon direct adenylyl cyclase activation with 
forskolin but not upon isoproterenol treatment, which suggests compartmentalized action of 
PDE1C which is not related to β-AR signaling. From these results one can speculate that 
PDE1C might preferentially degrade cAMP at the level of the myofilaments and the 
SERCA2 pump since Ca
2+ 
transient decay was also accelerated by ITI-214. Importantly, 
the inotropic effects of ITI-214 were not accompanied by an increase in Ca
2+ 
transient 
amplitude, thereby differing from the effects observed upon PDE3 inhibition. Thus, ITI-214 
may improve cardiac function without triggering the deleterious pro-arrhythmogenic effects 
that precludes chronic use of milrinone.
1 
However, ITI-214 was only tested by Hashimoto 
et al. with acute administration, so the safety of chronic administration still needs to be 
evaluated. In particular, there is a concern regarding the observed in vivo positive 
chronotropic effect of ITI-214 in the study by Hashimoto et al. given the general consensus 
that heart rate reduction (as seen with β-blockers) is needed to improve the clinical outcome 
in HF.
9
 
Another question arising from these two studies concerns the role of cGMP in the 
cardioprotective effects of PDE1C downregulation. This enzyme is activated by Ca
2+ 
and 
degrades both cGMP and cAMP, with similar affinities. It is thus conceivable that PDE1C 
acts as an integrator at the crossroads of cGMP-, cAMP- and Ca
2+
-mediated
5 
 
 
signals in cardiomyocytes. Interestingly, PDE1A was found to prevent hypertrophy induced 
by various neurohormonal stimuli, acting via cGMP/PKG rather than cAMP,
6 
most likely 
through NFAT phosphorylation by PKG.
10 
Furthermore, some of the lusitropic effects 
observed by Hashimoto et al. upon PDE1 inhibition may arise via PKG phosphorylation of 
TnI (Figure).
11
 
Phosphodiesterases and heart failure 
 
Numerous studies have shown decreased expression and/or activity of PDE3 and PDE4 in 
various models of cardiac hypertrophy and/or HF, including human HF.
1 
On the contrary, 
hypertrophy and/or HF is usually accompanied by an increase in expression and/or activity 
of PDE1A, PDE1C, as well as PDE2 and PDE5.
1 
The question is whether these changes are 
bystander players in pathological cellular remodeling, or whether they participate in an 
adaptive or maladaptive process. 
Upregulation of PDE1A and PDE5 in HF, two PDEs that preferentially (PDE1A) or 
exclusively (PDE5) hydrolyze cGMP, can clearly be seen as maladaptive. Indeed, cGMP is 
known to inhibit pathological cardiac remodeling
12 
, and transgenic mice with 
cardiomyocyte-specific overexpression of PDE5 are predisposed to adverse LV remodeling 
after myocardial infarction. On the contrary, pharmacological inhibition of PDE1
6 
or PDE5 
reduces hypertrophy and ameliorates cardiac pressure and volume overload.
6,13 
However, 
in a recent clinical trial, PDE5 inhibition in HF patients with preserved ejection fraction did 
not significantly improve exercise capacity or clinical status compared to the placebo 
group.
14 
It is thus necessary to identify new therapeutic targets, and PDE1 might be one of 
interest according to the two studies reported here.
3, 4 
These two studies also provide strong 
evidence that targeting phosphodiesterases remains a promising strategy in cardiac diseases. 
According to these two papers, PDE1C inhibition might be ideal, acting by concomitantly 
improving cardiac output of the failing pump, producing vasorelaxant effects and conferring 
cardioprotection by limiting apoptosis. This will hopefully be confirmed by an ongoing 
clinical trial with ITI-214 in systolic HF patients (NCT03387215) and should be fostered 
further by development of new, potent, and selective inhibitors of these enzymes.
15 
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Figure legend 
PDE1C inhibition promotes cardiac function and provides cardioprotection against pathological stimuli, such as Ang II 
or DOX. According to the model elaborated by Zhang et al., pathological stimuli activate TRPC3 to allow Ca2+ influx via TRPC3 
channels to promote PDE1C activity via Ca2+/CaM. As a result, the cardioprotective cAMP pool emanating from the adenosine 
receptor A2R is decreased. Whether the same cAMP compartment is responsible for the inotropic and lusitropic effects of ITI-214 
found by Hashimoto et al. remains to be explored. Also, the contribution of the cGMP/PKG signaling 
pathway needs to be examined. 
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